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Critical illness is often associated with reduced TSH and thy-
roid hormone secretion as well as marked changes in periph-
eral thyroid hormone metabolism, resulting in low serum T3
and high rT3 levels. To study the mechanism(s) of the latter
changes, we determined serum thyroid hormone levels and
the expression of the type 1, 2, and 3 iodothyronine deiodi-
nases (D1, D2, and D3) in liver and skeletal muscle from de-
ceased intensive care patients. To study mechanisms under-
lying these changes, 65 blood samples, 65 liver, and 66 skeletal
muscle biopsies were obtained within minutes after death
from 80 intensive care unit patients randomized for intensive
or conventional insulin treatment. Serum thyroid parameters
and the expression of tissue D1-D3 were determined. Serum
TSH, T4, T3, and the T3/rT3 ratio were lower, whereas serum
rT3 was higher than in normal subjects (P < 0.0001). Liver D1
activity was down-regulated and D3 activity was induced in
liver and skeletal muscle. Serum T3/rT3 ratio correlated pos-
itively with liver D1 activity (P < 0.001) and negatively with
liver D3 activity (ns). These parameters were independent of
the type of insulin treatment. Liver D1 and serum T3/rT3 were
highest in patients who died from severe brain damage, in-
termediate in those who died from sepsis or excessive inflam-
mation, and lowest in patients who died from cardiovascular
collapse (P < 0.01). Liver D3 showed an opposite relationship.
Acute renal failure requiring dialysis and need of inotropes
were associated with low liver D1 activity (P < 0.01 and P 
0.06) and high liver D3 (P < 0.01) and skeletal muscle D3 (P <
0.05) activity. Liver D1 activity was negatively correlated with
plasma urea (P  0.002), creatinine (P  0.06), and bilirubin
(P < 0.0001). D1 and D3 mRNA levels corresponded with en-
zyme activities (both P < 0.001), suggesting regulation of the
expression of both deiodinases at the pretranslational level.
This is the first study relating tissue deiodinase activities with
serum thyroid hormone levels and clinical parameters in a
large group of critically ill patients. Liver D1 is down-regu-
lated and D3 (which is not present in liver and skeletal muscle
of healthy individuals) is induced, particularly in disease
states associated with poor tissue perfusion. These observed
changes, in correlation with a low T3/rT3 ratio, may represent
tissue-specific ways to reduce thyroid hormone bioactivity
during cellular hypoxia and contribute to the low T3 syn-
drome of severe illness. (J Clin Endocrinol Metab 88:
3202–3211, 2003)
CRITICAL ILLNESS INDUCES a variety of hormonalchanges that differ between acute and prolonged crit-
ical illness (1). Striking alterations observed in acute critical
illness include increased serum catecholamines, GH, and
cortisol levels, a blunted GH pulsatility, insulin resistance,
and the so-called low T3 syndrome (1, 2). In prolonged crit-
ical illness, catecholamine and cortisol levels decrease, com-
pared with the acute situation, and a decrease in the levels
of GH, TSH, and thyroid hormone occurs. There are no
indications that the acute changes are harmful, but it is un-
clear whether the endocrine changes in prolonged critical
illness are all beneficial adaptations because recent data sug-
gest that some may contribute to a worsening of the clinical
condition (3).
Substitution of critically ill patients with high doses of GH,
corticosteroids, or thyroid hormone has been found to have
no or even a negative effect on clinical outcome (4–7). In a
recent study, it was shown that strict control of blood glucose
levels less than 110 mg/dl with intensive insulin therapy
markedly reduces morbidity and mortality in critically ill
patients (8). Endocrine intervention with hypothalamic re-
leasing factors, which restores pulsatile pituitary hormone
secretion and normalizes peripheral hormone levels, may be
another successful approach (3, 9).
In this study we focused on the peripheral metabolism of
thyroid hormone in critically ill patients. In critical illness,
serum T3 concentration decreases and serum rT3 increases,
the magnitudes of these changes being related to the severity
of disease (10). Although serum T4 and free T4 (FT4) may be
increased in mild illnesses, serum T4 is decreased, and FT4
normal or decreased in severely ill patients (10).
In humans, peripheral thyroid hormone metabolism is
mediated importantly by the three iodothyronine deiodi-
nases D1, D2, and D3 (see Refs. 11 and 12 for reviews). D1
is present in liver, kidney, and thyroid and plays a key role
in the production of serum T3 from T4 and in the breakdown
of the metabolite rT3 (11, 12). D2 is present in brain, pituitary,
thyroid, and skeletal muscle and also converts T4 by outer-
ring deiodination to T3. In tissues such as the brain, D2 is
important for local T3 production, but the enzyme in skeletal
muscle may also contribute to plasma T3 production (11, 12).
D3 is present in brain, skin, placenta, pregnant uterus, and
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various fetal tissues; it catalyzes the inactivation of T4 and T3
by inner-ring deiodination to rT3 and 3,3-diiodothyronine
(3,3-T2), respectively (11, 12).
The strongly reduced circulating T3 levels in sick patients
may be due in part to a decreased peripheral T4 deiodination
by D1, D2, or both (12–14). The increase in serum rT3 levels
is explained by a decrease in D1 activity because D1 is the
principal pathway for rT3 clearance (15). Besides a decreased
D1 activity, an impaired transport of T4 and rT3 into D1-
containing tissues such as liver may be another important
mechanism for the changes in thyroid hormone levels asso-
ciated with illness (16). However, the possibility that an
increased D3 activity contributes to the reduced serum T3
levels and increased rT3 levels should also be considered.
Patients with D3-expressing hemangiomas may have very
low serum T4 and T3 concentrations, combined with very
high serum rT3 levels (17). The term consumptive hypothy-
roidism is used for this syndrome. There are hitherto no data
on the eventual role of D3 induction in the low T3 syndrome
of severe illness.
In this study, serum samples and liver and skeletal muscle
biopsies were obtained from 80 patients within minutes after
they died in a surgical intensive care unit (ICU). The patients
had been randomized for intensive or conventional insulin
therapy as recently described (8). Tissue D1, D2, and D3 gene
expression and activity as well as serum TSH, T4, T3, and rT3
concentrations were measured. The correlations among these
analytes as well as their correlations with several clinical
parameters were calculated.
Materials and Methods
Materials
Nonradioactive iodothyronines were obtained from Henning (Berlin,
Germany). [3,5-125I]T4 (with a specific activity of ca. 2000 mCi/mol)
was obtained from Amersham Pharmacia (Rozendaal, The Nether-
lands). [3-125I]T3 and [3,5-125I]rT3 (with both a specific activity of ca.
2000 mCi/mol) were prepared by radioiodination of 3,5-T2 and 3,3-
T2, respectively (18). [125I]T4 and [125I]rT3 were purified immediately
before use by Sephadex LH-20 (Amersham Pharmacia) chromatography
(19). N-bromoacetyl-[125I]T3 (BrAc[125I]T3) was prepared as previously
described (20). Its purity was checked by HPLC analysis. Protein mo-
lecular weight markers, and 6-n-propyl-2-thiouracil (PTU) were ob-
tained from Sigma (Zwijndrecht, The Netherlands); dithiothreitol (DTT)
from ICN (Zoetermeer, The Netherlands); electrophoresis grade SDS-
PAGE reagents from Bio-Rad (Veenendaal, The Netherlands); Coomas-
sie Brilliant Blue R-250 from Merck (Darmstadt, Germany); and TaqMan
probes and primers from Biosource (Nivelles, Belgium). All other chem-
icals used in this study were of reagent grade.
Subjects
This study was part of a large randomized, controlled study on
intensive insulin treatment in ICU patients (n 1548), of which the major
clinical outcomes have been published in detail elsewhere (8). On ad-
mission, patients were randomly assigned to either strict normalization
of blood glucose (80–110 mg/dl) with intensive insulin therapy or the
conventional approach, in which insulin infusion is initiated only when
blood glucose exceeds 215 mg/dl, to maintain blood glucose levels
between 180 and 200 mg/dl. Maximal insulin dose was arbitrarily set at
50 IU/h. The study protocol has been approved by the Ethical Review
Board of the University of Leuven School of Medicine, and patients were
included after informed consent from the closest family member.
A total of 80 patients was included in this study. Blood samples were
obtained from 65 patients, liver biopsies from 66 patients, and skeletal
muscle (rectus abdominis) biopsies from 66 patients within minutes after
death [25.2 20.0 (sd), range (5–97 min) for liver and 20.7 19.7, range
(0–95 min) for skeletal muscle]. From 51 patients blood, liver, and
skeletal muscle samples were available. All patients had been random-
ized for conventional or intensive insulin treatment (8). Thirty-one pa-
tients had been treated with thyroid hormone during the course of their
critical illness when they had a serum T4 concentration less than 50
nmol/liter in the face of a normal thyroxine-binding globulin and con-
comitantly clinical symptoms of hypothyroidism, defined as coma or
central nervous system suppression, failure to wean from the ventilator,
or hemodynamic instability, which were unexplained and resistant to
conventional supportive therapy. In these cases, thyroid hormone treat-
ment consisted of an iv bolus of 150 g T4 daily plus 0.6 g T3 per kg
body weight per 24 h as a continuous iv infusion. All patients included
in this study had died in the ICU, and the cause of death was determined
both clinically by the attending ICU physician and postmortem exam-
ination. The pathologist was unaware of insulin treatment allocation.
Relevant patients’ characteristics are summarized in Table 1.
Serum analyses
The care of patients in the ICU often comprises infusion of heparin,
either systemically or locally to prevent clotting of vascular access, which
substantially interferes with the assay used to quantify free concentra-
tions of thyroid hormone (21). Therefore, we refrained from measuring
serum FT4 and free T3 in this study. Serum total T4, total T3, and TSH
were measured by chemoluminescence assays (Vitros ECi Immunodi-
agnostic System, Ortho-Clinical Diagnostics, Amersham, UK). The rT3
was measured by RIA as previously described (22). Within-assay coef-
ficients of variation amounted to 4% for TSH, 2% for T4, 2% for T3, and
3–4% for rT3. Normal values for TSH, T4, T3, and rT3 were determined
in 270 healthy individuals. Mean  2 sd was used as the normal range
for T4, T3, and rT3, whereas the 95% confidence interval was used
for TSH.
TABLE 1. Patients’ characteristics, divided in different groups based on cause of death
Cause of deatha
I II III IV Total
No. of patients 11 36 27 6 80
Age (yr) 66.6  11.1 70.2  12.4 68.7  12.8 62.1  9.0 68.6  12.1
BMI 28.4  6.1 24.9  3.5 25.2  5.4 23.6  3.0 25.4  4.7
ICU stay (days) 8.7  7.3 31.4  34.5 24.9  25.4 6.2  5.7 24.2  28.9
Male 5 26 20 4 55
Intensive insulin therapy 6 6 11 2 25
Thyroid hormone treatment 4 15 12 0 31
RRTb 4 20 14 2 40
Inotropes treatment 10 32 21 3 66
Data represent mean  SD.
a I, Cardiovascular collapse; II, MOF sepsis; III, MOF SIRS; IV, severe brain damage.
b RRT, renal replacement therapy: hemodialysis or hemofiltration.
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Deiodinase activities
Human liver and skeletal muscle samples were homogenized on ice
in 10 volumes of PE buffer [0.1 m phosphate and 2 mm EDTA (pH 7.2)]
using a Polytron (Kinematica AG, Lucerne, Switzerland). Homogenates
were snap frozen in aliquots and stored at 80 C until further analysis.
Protein concentration was measured with the Bio-Rad protein assay
using BSA as the standard following the manufacturer’s instructions.
Liver D1 activities were determined as described earlier (23) by du-
plicate incubations of homogenates (10 g protein) for 30 min at 37 C
with 0.1 m [3,5-125I]rT3 (100,000 cpm) in a final volume of 0.1 ml
PED10 buffer (PE  10 mm DTT). To validate the specificity of the D1
assay, some incubations were also carried out in the presence of 0.1 mm
of the D1 inhibitor PTU or excess unlabeled rT3 (1 m). Reactions were
stopped by addition of 0.1 ml 5% (wt/vol) BSA in water on ice. The
protein-bound iodothyronines were precipitated by addition of 0.5 ml
ice-cold 10% (wt/vol) trichloroacetic acid in water. Following centrif-
ugation, 125I was isolated from the supernatant by chromatography
on Sephadex LH-20 minicolumns (24). Skeletal muscle D1 activities
were assayed similarly, using 200 g homogenate protein in a 60-min
incubation.
Liver and skeletal muscle D2 activities were assayed as earlier de-
scribed (25) by duplicate incubation of 200 g homogenate protein for
60 min at 37 C with 1 nm [3,5-125I]T4 (100,000 cpm) in a final volume
of 0.1 ml PED25 buffer (PE 25 mm DTT). The incubations were carried
out in the presence of 0.1 m unlabeled T3, to prevent inner-ring deio-
dination of the labeled T4 substrate by D3, if present, and in the absence
or presence of 0.1 m unlabeled T4, which is sufficient to saturate D2.
Deiodination of labeled T4 in the absence minus that in the presence of
excess unlabeled T4 represents D2 activity. The further procedure for the
quantitation of 125I production was the same as described above for the
D1 assay.
Tissue D3 activities were measured as described earlier (24) by du-
plicate incubation of liver (100 g protein) or skeletal muscle (200 g
protein) homogenate for 60 min at 37 C with 1 nm [3-125I]T3 (200,000
cpm) in a final volume of 0.1 ml PED50 buffer. To validate the D3 assay,
some incubations were also carried out in the presence of 10 or 100 nm
unlabeled T3. Reactions were stopped by addition of 0.1 ml ice-cold
methanol. After centrifugation, 0.15 ml of the supernatant was added to
0.1 ml 0.02 m ammonium acetate (pH 4), and 0.1 ml of the mixture was
applied to a 4.6  250 mm Symmetry C18 column connected to an
Alliance HPLC system (Waters, Etten-Leur, The Netherlands). The col-
umn was eluted with a linear gradient of acetonitrile (28%–42% in 15
min) in 0.02 m ammonium acetate (pH 4.0) at a flow of 1.2 ml/min. The
radioactivity in the eluate was measured on-line using a Radiomatic
A-500 flow scintillation detector (Packard, Meriden, CT).
Affinity labeling
Affinity labeling of liver D1 was done as previously described (23) in
samples with low, intermediate, or high D1 activity. Briefly, homogenate
(100 g protein) was incubated for 15 min at 37 C with 100,000 cpm (25
fmol) BrAc[125I]T3 in 75l PED1 buffer (PE 1 mm DTT). To specifically
block affinity labeling of D1 protein, some incubations were carried out
in the presence of 10 m rT3 and 100 m PTU (23). Labeling was stopped
by the addition of SDS-loading buffer and heating the mixture for 5 min
at 80 C. Proteins (100 g per lane) were separated by SDS-PAGE gel
electrophoresis in a 12% resolving, 5% stacking gel (23). Gels were
stained with Coomassie Brilliant Blue R-250, dried at 80 C under vac-
uum, and autoradiographed by exposure overnight at80 C to Biomax
imaging film (Eastman Kodak, Rochester, NY).
RNA isolation and reverse transcription (RT)
RNA was isolated from liver samples using the High Pure RNA tissue
kit (Roche Diagnostics, Almere, The Netherlands) according to the man-
ufacturer’s protocol. RNA concentrations were determined using the
RiboGreen RNA quantitation kit (Molecular Probes, Leiden, The Neth-
erlands). All samples were diluted to 0.1 g/l, and 1 g was used for
cDNA synthesis using the TaqMan RT kit (Roche Diagnostics).
Real-time RT-PCR
D1 and D3 mRNA levels were determined in a set of liver samples
with low, intermediate, and high deiodinase activities. The ABI PRISM
7700 sequence detection system (Applied Biosystems, Nieuwerkerk aan
den IJssel, The Netherlands) was used, which uses TaqMan chemistry
for highly accurate quantitation of mRNA levels. Sequences and con-
centrations of the primers and probes are given in Table 2. Hepatic D1
and D3 mRNA levels are expressed relative to those of the glyceralde-
hyde-3-phosphate dehydrogenase housekeeping gene. The glyceralde-
hyde-3-phosphate dehydrogenase probe and primers were provided as
preoptimized control system (Applied Biosystems).
Reactions were done for 2 min at 50 C and for 10 min at 95 C, followed
by 40 cycles of 15 sec at 95 C and for 1 min at 60 C. According to the
manufacturer’s guidelines, data were expressed as cycle threshold (Ct)
values, which represent the cycle number at which probe-derived dye
absorbance reaches the calculated threshold value. Data are expressed
as Ct (i.e. the Ct value of the target gene minus the Ct value of the
housekeeping gene).
Statistical analysis
Data were analyzed using the statistical program SPSS 10.0.7 for
Windows (SPSS Inc., Chicago, IL). Logarithmic transformations were
applied to normalize variables and minimize the influence of outliers,
when appropriate. All analyses were done on the whole group as well
as on subgroups treated or not treated with thyroid hormone. Data were
analyzed using one-way ANOVA tests, with a post hoc Fisher’s least
significant difference test for multiple comparisons, t tests, Mann-Whit-
ney U tests, and linear regression analyses, when appropriate.
Results
Compared with the normal ranges for our laboratory, se-
rum TSH, T4, and T3 levels and the T3/rT3 ratio were low,
whereas mean serum rT3 was high (P 	 0.0001) (Table 3).
Patients who were treated with thyroid hormone had higher
serum T3 and lower TSH levels than patients who were not
treated with thyroid hormone. Serum T4 and rT3 levels were
not different between these groups. No significant correla-
tion was observed among serum TSH, T4, T3, and rT3 and
postmortem time.
Significant D1 activities were measured in all liver sam-
ples, with a range of 0.44–17.5 pmol/min per milligram
protein. In the liver samples tested, deiodination of the sub-
strate rT3 was completely blocked by addition of the D1-
specific inhibitor PTU and was largely saturated by increas-
ing the rT3 concentration from 0.1 to 1.1m. The approximate
TABLE 2. Sequences and concentrations of primers and probes that were used for determination of D1 and D3 mRNA levels by
quantitative real-time RT-PCR
Primers and
probes Sequence Concentration
D1 forward 5-TTAGTTCCATAGCAGATTTTCTTGTCA-3 200 nM
D1 reverse 5-CTGATGTCCATGTTGTTCTTAAAAGC-3 200 nM
D1 probe 5-FAM-AGCCATCTGATGCATGTGCTTCTTCAATG-TAMRA-3 100 nM
D3 forward 5-TTCCAGAGCCAGCACATCCT-3 200 nM
D3 reverse 5-ACGTCGCGCTGGTACTTAGTG-3 200 nM
D3 probe 5-FAM-TGCACCTGACCACCGTTCATGGC-TAMRA-3 200 nM
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Michaelis constant value for rT3 was 0.4  0.1 m (mean 
sd, n  4), which is in good agreement with previous data
(11, 12). Negligible D1 activities were observed in the skeletal
muscle homogenates. D2 activities were undetectable in all
liver and skeletal muscle biopsies.
Significant D3 activities were detected in most tissue sam-
ples, with ranges of 0.1–9.2 and 0.1–1.7 fmol/min per mil-
ligram protein in liver and skeletal muscle, respectively. In
both tissues, D3 activity was progressively saturated by in-
creasing the T3 concentration from 1 to 10 and 100 nm, pro-
viding approximate Michaelis constant values of 3.6 0.6 nm
T3 in liver and 2.3  0.6 nm T3 for skeletal muscle (mean 
sd, n 4). These values are in close agreement with previous
reports (11, 12). There was a significant correlation between
D3 expression in liver and skeletal muscle (R  0.54, P 	
0.001), but in some patients high expression in liver was
observed with low expression in skeletal muscle and vice
versa. No significant correlation was observed between deio-
dinase activities and postmortem time.
Serum thyroid hormone levels and tissue deiodinase ac-
tivities were not different between the patients who had
received intensive or conventional insulin therapy (Table 4).
This has been found in the whole group and separately in the
groups of patients who did or did not receive thyroid hor-
mone treatment.
All regression analyses were also performed on the whole
group and separately on the groups of patients who did or
did not receive thyroid hormone treatment. Unless men-
tioned specifically, similar correlations were observed in the
treated and untreated groups. The serum T3/rT3 ratio
showed a positive correlation with liver D1 activity (linear
regression test, R  0.66, P 	 0.001) and a negative, insig-
nificant correlation with liver D3 activity (P  0.17) (Fig. 1)
Serum T3/rT3 was not correlated with muscle D3 activity.
The possible relationships of tissue deiodinase activities
with serum iodothyronine parameters other than the T3/rT3
ratio were also analyzed. Surprisingly, liver D1 activity
showed a positive correlation with serum T4. This was due
to the strong relationship in thyroid hormone-treated pa-
tients (R 0.74, P 0.002), whereas no correlation was seen
in patients who had not received thyroid hormone (P 0.49).
Liver D1 activity showed a negative correlation with serum
rT3 (R  0.48, P 	 0.001) and the serum rT3/T4 ratio (R 
0.55, P 	 0.001), independent of thyroid hormone treat-
ment. Liver D1 activity was not correlated with serum T3 but
showed an unexpected negative correlation with the serum
T3/T4 ratio that was stronger in patients who had been
treated vs. those who had not been treated with thyroid
hormone (R  0.68, P  0.005 vs. R  0.44, P  0.008).
Liver D3 activity showed a positive correlation with serum
rT3 (R  0.40, P  0.016) and the rT3/T4 ratio (R  0.55, P 
0.001) in the group of patients who had not been treated with
thyroid hormone. These correlations were completely absent
in the group of patients who had received thyroid hormone
treatment. Skeletal muscle D3 activity showed a positive
correlation with the serum rT3/T4 ratio (R 0.55, P 0.001).
No other correlations were found for liver or skeletal muscle
D3 activity with serum iodothyronine levels.
Hepatic D1 activity showed a significant correlation with
cause of death, being lowest in the patients who had died of
a cardiovascular collapse, with successive increases in the
patients who had died of multiple organ failure (MOF) with
sepsis or MOF with systemic inflammatory response syn-
drome (SIRS) and being highest in the patients who had died
TABLE 3. Descriptive statistics of thyroid hormone levels and deiodinase activities in this population, subdivided in a group not receiving
thyroid hormone (TH) treatment and a group receiving TH treatment
TH treatment Mean Median SD Range Normal values Pa
TSH (mU/liter) 0.75 0.17 1.58 (0.001–10.7) 0.2–4.2 	0.0001
No (n  39) 1.12 0.61 1.91 (0.003–10.7)
Yes (n  25) 0.18b 0.01 0.48 (0.001–2.15)
T4 (nmol/liter) 46.3 40.6 28.8 (5.4–121) 58–128 	0.0001
No (n  39) 45.2 38.8 30.5 (5.4–121)
Yes (n  25) 48.0 44.7 26.4 (9.6–98.1)
T3 (nmol/liter) 1.24 0.98 0.79 (0.41–4.71) 1.43–2.51 	0.0001
No (n  39) 1.01 0.78 0.76 (0.41–4.71)
Yes (n  25) 1.60b 1.41 0.72 (0.67–3.21)
rT3 (nmol/liter) 1.85 1.37 2.15 (0.22–15.78) 0.14–0.34 	0.0001
No (n  39) 1.75 1.13 2.56 (0.22–15.78)
Yes (n  25) 1.99 1.85 1.31 (0.41–5.44)
T3/rT3 (molar ratios) 1.23 0.83 1.20 (0.18–6.13) 4.2–17.9 	0.0001
No (n  39) 1.25 0.70 1.28 (0.18–6.13)
Yes (n  25) 1.20 0.90 1.07 (0.31–4.81)
Liver D1 (pmol/mg  min) 4.51 3.25 3.89 (0.44–17.53)
No (n  44) 4.57 3.33 3.65 (0.52–16.78)
Yes (n  21) 4.40 2.55 4.43 (0.44–17.53)
Liver D3 (fmol/mg  min) 1.04 0.60 1.43 (0.14–9.15)
No (n  44) 0.97 0.51 1.19 (0.15–5.60)
Yes (n  21) 1.18 0.71 1.87 (0.14–9.15)
Muscle D3 (fmol/mg  min) 0.23 0.14 0.29 (0.06–1.65)
No (n  43) 0.26 0.13 0.32 (0.06–1.65)
Yes (n  22) 0.23 0.16 0.24 (0.09–1.14)
rT3, Reverse T3. To convert values for T4 to micrograms per deciliter, divide by 12.87; to convert values for T3 and rT3 to nanograms per
deciliter, divide by 0.0154.
a P values (t test) represent serum thyroid parameters of this population compared with normal values used in our laboratory.
b P 	 0.01 vs. untreated group.
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of severe brain damage (ANOVA P 	 0.01). Liver D1 activ-
ities in the latter group were similar to those determined in
normal liver samples (data not shown). The serum T3/rT3
ratio showed a similar positive correlation with cause of
death (ANOVA P 	 0.01), whereas liver D3 activity showed
an insignificant negative correlation (ANOVA P  0.2) with
cause of death. These relationships were strongest in the
group of patients who had not been treated with thyroid
hormone (Fig. 2), but similar correlations were also found in
the group of patients who had been treated with thyroid
hormone. D3 activities in skeletal muscle did not correlate
with cause of death.
Liver D1 activity was significantly lower in patients with
acute renal failure requiring renal replacement therapy
(RRT) such as dialysis or hemofiltration and in those receiv-
ing inotropes, compared with those who did not require
these treatments (Mann-Whitney U test, P 	 0.01 for both)
(Figs. 3 and 4). Liver D3 activity was higher in patients who
had been treated with inotropes (Mann-Whitney U test, P 	
0.05) or RRT (P  0.056) (Figs. 3 and 4). Muscle D3 activity
was also higher in patients who had been treated with ino-
tropes (Mann-Whitney U test, P 	 0.05) (Fig. 4). Correction
for treatment with dopamine did not affect these correla-
tions. Liver D1 activity was negatively correlated with
plasma urea (R0.35, P 0.01) and with plasma creatinine
(R0.27, P 0.06) (Fig. 5). A remarkably strong, negative
correlation was found for liver D1 activity with plasma total
bilirubin (R0.54, P	 0.0001) (Fig. 6). D3 activities in liver
and skeletal muscle showed no relationship with plasma
urea, creatinine, or bilirubin levels. No correlation was found
of liver D1, liver D3, or skeletal muscle D3 activity with
plasma C-reactive protein levels.
Affinity labeling of the 27-kDa D1 protein in liver homog-
enates using BrAc[125I]T3 showed a good correlation with the
D1 activities determined in the same samples (Fig. 7). Af-
finity labeling of D1 but not of other proteins was blocked by
the addition of PTU and unlabeled rT3 (not shown), in sup-
port of the specificity of the affinity labeling of D1 with
BrAc[125I]T3. Liver D1 and D3 mRNA levels determined by
real-time quantitative RT-PCR were significantly correlated
with the corresponding deiodinase activities (R  0.74, P 	
0.001, for D1; R  0.78, P 	 0.001 for D3) (Fig. 8).
Discussion
Critical illness is associated with reduced TSH and thyroid
hormone secretion as well as with marked changes in pe-
ripheral thyroid hormone metabolism, resulting in low cir-
culating T3 and high rT3 levels (10). Both the fall in serum T3
and the rise in rT3 have been found to correlate with severity
of illness (10) and decreased serum T4 has been associated
with poor prognosis. Inactivation of thyroid hormone is pre-
sumed to reflect an adaptive response of the body to conserve
tissue function. As expected, we found low serum levels of
TSH, total T4 and T3, high levels of rT3, and a low active over
inactive thyroid hormone (T3/rT3) ratio in the studied crit-
ically ill patients. Liver D1 activity was down-regulated and
liver and skeletal muscle D3 activity, not present in healthy
individuals, was induced. Changes in tissue deiodinase ac-
tivities, particularly pronounced in conditions characterized
by low tissue perfusion, were statistically correlated with the
altered circulating thyroid hormone levels, suggesting a role
in the pathophysiology of the low T3 syndrome of severe
illness. Previous studies have suggested large changes in
serum thyroid hormone levels after death (26). However,
correlations observed in our study cannot be explained by
TABLE 4. The effect of insulin treatment on serum thyroid parameters and deiodinase activities
Intensive insulin
treatment Mean Median SD Range Normal values
Mann-Whitney
U Pa
TSH (mU/liter) 0.2–4.2
No (n  48) 0.93 0.21 1.79 0.001–10.7 0.08
Yes (n  16) 0.23 0.05 0.30 0.002–0.79
T4 (nmol/liter) 58–128
No (n  48) 25.3 43.1 28.0 5.4–121 0.66
Yes (n  16) 49.3 37.4 31.7 18.8–118
T3 (nmol/liter) 1.43–2.51
No (n  48) 1.19 0.96 0.68 0.41–3.21 0.64
Yes (n  16) 1.40 1.14 1.08 0.51–4.71
rT3 (nmol/liter) 0.14–0.34
No (n  48) 1.73 1.52 1.32 0.24–5.44 0.48
Yes (n  16) 2.19 1.37 3.72 0.22–15.78
T3/rT3 (molar ratio) 4.2–17.9
No (n  48) 1.21 0.72 1.28 0.18–6.13 0.34
Yes (n  16) 1.27 1.09 0.91 0.30–3.29
Liver D1 (pmol/mg  min)
No (n  43) 4.46 3.25 4.12 0.52–17.53 0.73
Yes (n  22) 4.61 3.21 3.48 0.44–11.44
Liver D3 (fmol/mg  min)
No (n  43) 1.18 0.60 1.72 0.15–9.15 0.93
Yes (n  22) 0.76 0.62 0.46 0.14–1.84
Muscle D3 (fmol/mg  min)
No (n  42) 0.28 0.14 0.36 0.06–1.65 0.24
Yes (n  23) 0.15 0.13 0.07 0.06–0.30
rT3, Reverse T3. To convert values for T4 to micrograms per deciliter, divide by 12.87; to convert values for T3 and rT3 to nanograms per
deciliter, divide by 0.0154.
a P values (Mann-Whitney U test) represent intensive insulin treatment vs. conventional insulin treatment.
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differences in postmortem time because no relation of post-
mortem time with deiodinase activities or serum thyroid
parameters was observed.
In healthy subjects, about 20% of circulating T3 is secreted
by the thyroid. Estimates of the contribution of liver and
kidney D1 to peripheral T3 production vary from 15% to 80%
(12), with the remainder of extrathyroidal T3 production
originating in D2-containing tissues such as skeletal muscle.
The contribution of D1 seems to be highest in hyperthyroid
patients, whereas D2 may play a more important role in
euthyroid and, in particular, hypothyroid subjects (12). A
low D1 activity will result in not only a decreased production
of T3 from T4 but also reduced clearance of rT3 because D1
is the principal pathway for rT3 clearance (12). A decreased
uptake of T4 and rT3 into D1-expressing tissues is another
possible mechanism to lower serum T3 and increase serum
rT3 levels (10, 15, 16). Furthermore, the activity of the dif-
ferent deiodinases greatly depends on thiol cofactors, al-
though the physiological cofactor(s) for each deiodinase has
not been identified (11, 12). In our study, tissue deiodinase
activities were determined in the presence of excess exoge-
nous cofactor (DTT). Our studies, therefore, do not provide
information about changes in the availability of the natural
cofactors as a possible mechanism for the changes in periph-
eral thyroid hormone metabolism in critical illness.
In normal healthy subjects, only D1 is expressed in liver
and preliminary data suggest that D2 activity is expressed in
skeletal muscle (12). In liver of critically ill patients, we found
D1 activity, which, except for patients who died acutely from
severe brain damage, was low, compared with values ob-
served in healthy individuals, and also substantial D3 ac-
tivity. As expected, D2 activity could not be detected in liver.
FIG. 1. Correlation of liver D1 (A) and liver D3 (B) activities with the
serum T3/rT3 ratio in 65 patients. No distinction is made in this figure
between patients who received thyroid hormone treatment and pa-
tients who did not. Liver D1 shows a significant positive correlation
with T3/rT3 ratio (P	 0.001), whereas liver D3 shows an insignificant
negative trend (P  0.17).
FIG. 2. Correlation of liver D1 (A) and liver D3 (B) activities, and the
T3/rT3 ratio (C) with cause of death in patients who were not treated
with thyroid hormone. Patients are divided into four different groups
based on cause of death. I, Cardiovascular collapse (n 5); II, multiple
organ failure with sepsis (n  21); III, multiple organ failure with
systemic inflammatory response syndrome (n  14); IV, severe brain
damage (n  4). Liver D1 activity and serum T3/rT3 ratio showed a
significant relation with cause of death (P 	 0.01), whereas liver D3
activity showed an opposite trend. **, P	 0.01 vs. group I; *, P	 0.05
vs. group I. Data represent means  SEM and P values were obtained
with ANOVA and Fisher’s least significant difference for multiple
comparisons.
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Surprisingly, skeletal muscle of critically ill patients showed
a significant D3 activity, whereas both muscle D1 and D2
activities were negligible. In general, the expression of D1
and D3 is up-regulated and that of D2 is down-regulated by
thyroid hormone (11, 12). Based on the low serum thyroid
hormone levels in our patients, a high D2 expression and a
low D1 and D3 expression would be expected. Although we
did observe mostly low hepatic D1 expression, D2 activity in
skeletal muscle was undetectable, and liver and skeletal mus-
cle samples expressed substantial D3 activities. Hence, a role
of regulators other than thyroid hormone is suggested.
To reduce the confounding effect of variable concentra-
tions of T4 and T4-binding proteins, we mainly focused on the
correlation of tissue deiodinase activities with serum iodo-
thyronine ratios. Because a low D1 expression conceivably
reduces T3 production and rT3 clearance and because ele-
vated D3 expression enhances T3 clearance and rT3 produc-
tion, the serum T3/rT3 ratio is the parameter that most ac-
curately reflects the result of altered peripheral thyroid
hormone metabolism during critical illness. Our data suggest
an important role of liver D1 in inducing the altered thyroid
hormone levels of critically ill patients because liver D1 ac-
tivity was positively correlated with serum T3/rT3 ratio and
negatively correlated with the serum rT3/T4 ratio. Surpris-
ingly, liver D1 activity also showed a negative correlation
with the serum T3/T4 ratio. This is due in part to the positive
correlation between liver D1 activity and serum T4 levels in
the thyroid hormone-treated group, which may be explained
by the positive control of D1 expression by thyroid hormone,
although this is thought to be mediated by T3 (12, 27). Liver
FIG. 3. Liver D1 (A) and liver D3 (B) activities in patients with acute
renal failure requiring RRT (n 33) and patients who did not require
this treatment (n  32). Liver D1 was significantly lower in patients
who required RRT (P 	 0.01), whereas liver D3 activity was higher
(P  0.06). Box plots represent 10th-25th-50th-75th-90th percentile,
and P values were obtained with Mann-Whitney U test.
FIG. 4. Liver D1 (A) and liver D3 (B) activities in patients receiving
inotropes (n  54) and patients who did not require this treatment
(n  11). Liver D1 was significantly lower in patients who required
inotropes (P	 0.01), whereas liver D3 activity was higher (P	 0.01).
Skeletal muscle D3 activity (C) was also higher (P	 0.05) in patients
who were treated with inotropes (n  53) than in patients who were
not (n  12). Box plots represent 10th-25th-50th-75th-90th percen-
tiles, and P values were obtained with Mann-Whitney U test.
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D3 activity correlated positively with serum rT3/T4 and
tended to correlate negatively with serum T3/rT3. Normally,
D3 is present only in human liver during fetal development,
in which it protects the fetus from undue exposure to thyroid
hormone, suggesting that pathological conditions in adult
life may be associated with changes in deiodinase expression,
in particular that of D3, to levels occurring during fetal de-
velopment (24, 28). There are two ways by which D3 de-
creases T3 availability: It prevents conversion of T4 to T3 by
catalyzing the conversion of T4 to rT3 instead, and it also
catalyzes the degradation of T3 to 3,3-T2. Therefore, induc-
tion of liver D3 in critically ill patients is likely to contribute
to the low serum T3 and high serum rT3 levels in critically ill
patients.
There is evidence that D2 is expressed in skeletal muscle
of healthy subjects (25). D2 activity is regulated by substrate-
induced enzyme inactivation (12). Hence, it may be surpris-
ing that we failed to detect significant D2 activity in skeletal
muscle of critically ill patients, particularly in view of the low
serum T4 levels. However, critically ill patients have strongly
increased serum rT3 concentrations, which may also inacti-
vate D2 (29). Another explanation for the lack of D2 activity
is the short half-life of functional D2 protein (	1 h in eu-
thyroid conditions), which may cause rapid postmortem D2
inactivation (12). However, because in this study tissue bi-
opsies were taken within minutes after death, postmortem
decay of D2 activity should be minimal. The shortest interval
between entry in the ICU and isolation of tissue samples was
between 24 and 48 h. Thus, in view of the short half-life of
the D2 protein, it may well have disappeared from skeletal
muscle if its expression is acutely suppressed in severe ill-
ness. It is also possible that D2 expression varies between
different types of skeletal muscle, but this remains to be
investigated. Like D1, D2 is a thyroid hormone-activating
enzyme. Therefore, the lack of D2 activity in skeletal muscle,
as does the down-regulation of hepatic D1 activity, may
contribute to low serum T3 levels in critically ill patients.
Another surprising finding was the expression of substan-
tial D3 activity in skeletal muscle. Muscle D3 activity was
significantly correlated with serum rT3/T4 ratio, but not with
T3/rT3 ratio, in critically ill patients. Although D3 activity has
been reported previously in fetal rat muscle (30), this is the
first report of D3 expression in human skeletal muscle. By
converting T4 to rT3 and T3 to 3,3-T2, D3 may lower local
thyroid hormone levels in skeletal muscle. It has been shown
recently that expression of D3 in hemangiomas may result in
very low serum T4 and T3 and very high rT3 levels (17).
Because skeletal muscle is such an abundant tissue in hu-
mans, it is likely that induction of D3 in skeletal muscle also
contributes to the low serum T4 and T3 and high rT3 levels
in critical illness.
No significant differences in tissue deiodinase expression
were observed between patients who had been treated with
intensive or conventional insulin therapy. This seems to con-
tradict the marked beneficial effects of intensive insulin ther-
apy on morbidity and mortality in intensive care patients (8).
However, it should be noted that the current study involved
postmortem samples. The illness of patients who died after
being intensively treated with insulin was therefore at least
as severe as that of patients who died after having received
conventional insulin therapy.
Liver D1 activity and serum T3/rT3 ratio showed a sig-
nificant relationship with cause of death. Cause of death was
categorized in four different groups, with group 1 having the
most severe, and group 4 the least hemodynamic instability
before death. Hepatic D1 activity and serum T3/rT3 were
lowest in patients who died of a cardiovascular collapse
(group 1) and were highest in patients who died of severe
brain damage (group 4). Liver D3 showed an opposite, in-
significant correlation with cause of death. Because ICU stay
was shorter in groups 1 and 4 than in groups 2 and 3 (MOF
with sepsis and MOF with SIRS), these correlations cannot be
explained by the duration of the illness. These data suggest
that the observed changes in liver deiodinase activity may
FIG. 6. Correlation of liver D1 activity with serum bilirubin levels (on
the last day) in 65 patients. Liver D1 activity showed a significant
negative correlation with serum bilirubin levels (P 	 0.0001).
FIG. 5. Correlation of liver D1 activity with plasma creatinine and
plasma urea levels (on the last day) in 65 patients. Liver D1 activity
showed a negative trend with plasma creatinine (P  0.06) and a
negative correlation with plasma urea levels (P  0.01).
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relate to poor tissue perfusion. For this reason, we analyzed
the relation of tissue deiodinase activities with several other
clinical parameters related to a decreased tissue perfusion,
such as decreased kidney function (plasma urea and creat-
inine), the need for renal replacement therapy (dialysis or
hemofiltration), the need for inotropes, and impaired liver
function (plasma total bilirubin). Liver D1 activity was neg-
atively correlated with plasma urea and creatinine. Patients
with acute renal failure requiring dialysis/hemofiltration
and those requiring inotropes for hemodynamic stability had
lower liver D1 activities and higher liver D3 activities than
patients who did not require these treatments. Skeletal mus-
cle D3 activity was also higher in patients treated with ino-
tropes. Although dopamine is known to inhibit TSH secre-
tion and peripheral T4 to T3 conversion (31), correction for
dopamine did not affect these correlations. Liver D1 activity
showed a very strong negative correlation with plasma total
bilirubin, whereas no correlation was shown with inflam-
mation as reflected by an elevated CRP level. To our knowl-
edge, there are no previous data suggesting a relation be-
tween deiodinase activity and tissue hypoxia, but a pH
dependence of D1 activity has been shown in perfused rat
livers (32). Because D1 is responsible for the activation and
D3 for the inactivation of thyroid hormone, regulation of
deiodinase activities by cellular hypoxia may be a tissue-
specific way to alter thyroid hormone bioactivity during
limited oxygen supply.
Our data regarding hepatic deiodinase activities were sub-
stantiated by a good correlation with liver D1 and D3 mRNA
levels and affinity labeling of the D1 protein with N-
bromoacetyl-[125I]T3. This suggests that the changes in liver
D1 and D3 expression in severely ill patients are largely
exerted at the pretranslational level.
In conclusion, this is the first report on the relationships
among tissue deiodinase activities, thyroid hormone levels,
and clinical parameters in a large group of critically ill pa-
tients. Liver D1 activity is down-regulated, and liver and
skeletal muscle D3, both not present in healthy subjects, are
induced, particularly in those disease states with poor tissue
perfusion and unrelated to inflammation. The data suggest
that low D1 activity plays an important role in the altered
thyroid hormone levels during critical illness. The induction
of D3 in liver and skeletal muscle of critically ill patients
suggests a role of this enzyme in pathophysiology, which
may be more important than previously thought. Indeed,
high D3 activity in an abundant tissue such as skeletal muscle
is likely to lower circulating T4 and T3 and increase rT3
levels, hence contributing to the low T3 syndrome of severe
illness.
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